253 related articles for article (PubMed ID: 30941350)
1. Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy.
Ouboussad L; Burska AN; Melville A; Buch MH
Front Med (Lausanne); 2019; 6():45. PubMed ID: 30941350
[TBL] [Abstract][Full Text] [Related]
2. Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis.
Holdsworth EA; Donaghy B; Fox KM; Desai P; Collier DH; Furst DE
Rheumatol Ther; 2021 Dec; 8(4):1637-1649. PubMed ID: 34487340
[TBL] [Abstract][Full Text] [Related]
3. Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology.
Astorri E; Nerviani A; Bombardieri M; Pitzalis C
Curr Pharm Des; 2015; 21(17):2216-24. PubMed ID: 25760296
[TBL] [Abstract][Full Text] [Related]
4. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
5. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
[TBL] [Abstract][Full Text] [Related]
6. Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis.
Das P; Weisenfeld D; Dahal K; De D; Feathers V; Coblyn JS; Weinblatt ME; Shadick NA; Cai T; Liao KP
Arthritis Res Ther; 2023 Jun; 25(1):93. PubMed ID: 37269020
[TBL] [Abstract][Full Text] [Related]
7. Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database.
Hepworth E; Movahedi M; Rampakakis E; Mirza R; Lau A; Cesta A; Pope J; Sampalis JS; Bombardier C
Curr Rheumatol Rev; 2021; 17(3):349-359. PubMed ID: 33308132
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts.
Hazlewood GS; Bombardier C; Li X; Movahedi M; Choquette D; Coupal L; Bykerk VP; Schieir O; Mosher D; Marshall DA; Bernatsky S; Spencer N; Richards DP; Proulx L; Barber CEH;
J Rheumatol; 2022 Jan; 49(1):16-25. PubMed ID: 34334357
[TBL] [Abstract][Full Text] [Related]
9. New learnings on the pathophysiology of RA from synovial biopsies.
Pitzalis C; Kelly S; Humby F
Curr Opin Rheumatol; 2013 May; 25(3):334-44. PubMed ID: 23492740
[TBL] [Abstract][Full Text] [Related]
10. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY
Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964
[TBL] [Abstract][Full Text] [Related]
11. Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.
Singh JA; Cameron DR
J Manag Care Pharm; 2012 May; 18(4 Supp C):S1-18. PubMed ID: 22656072
[TBL] [Abstract][Full Text] [Related]
12. Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugs.
Valor L; Garrido J; Martínez-Estupiñán L; Hernández-Flórez D; Janta I; López-Longo FJ; Monteagudo I; González CM; Naredo E
Rheumatol Int; 2018 Aug; 38(8):1465-1470. PubMed ID: 29915991
[TBL] [Abstract][Full Text] [Related]
13. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.
Dennis G; Holweg CT; Kummerfeld SK; Choy DF; Setiadi AF; Hackney JA; Haverty PM; Gilbert H; Lin WY; Diehl L; Fischer S; Song A; Musselman D; Klearman M; Gabay C; Kavanaugh A; Endres J; Fox DA; Martin F; Townsend MJ
Arthritis Res Ther; 2014; 16(2):R90. PubMed ID: 25167216
[TBL] [Abstract][Full Text] [Related]
14. Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.
Humby F; Lewis M; Ramamoorthi N; Hackney JA; Barnes MR; Bombardieri M; Setiadi AF; Kelly S; Bene F; DiCicco M; Riahi S; Rocher V; Ng N; Lazarou I; Hands R; van der Heijde D; Landewé RBM; van der Helm-van Mil A; Cauli A; McInnes I; Buckley CD; Choy EH; Taylor PC; Townsend MJ; Pitzalis C
Ann Rheum Dis; 2019 Jun; 78(6):761-772. PubMed ID: 30878974
[TBL] [Abstract][Full Text] [Related]
15. Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients.
Burkard T; Williams RD; Vallejo-Yagüe E; Hügle T; Finckh A; Kyburz D; Burden AM
Rheumatol Adv Pract; 2021; 5(3):rkab087. PubMed ID: 34888435
[TBL] [Abstract][Full Text] [Related]
16. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors.
Rivellese F; Lobasso A; Barbieri L; Liccardo B; de Paulis A; Rossi FW
Curr Med Chem; 2019; 26(16):2823-2843. PubMed ID: 29424301
[TBL] [Abstract][Full Text] [Related]
18. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
[TBL] [Abstract][Full Text] [Related]
19. Treatment of rheumatoid arthritis: Unraveling the conundrum.
Zampeli E; Vlachoyiannopoulos PG; Tzioufas AG
J Autoimmun; 2015 Dec; 65():1-18. PubMed ID: 26515757
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
